Ingevity Corporation (NGVT) has a negative trailing P/E of -15.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 15.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -6.37%, forward earnings yield 6.42%. PEG 0.99 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 65.6 | -1.17 | 17.16 | 2.54 | - |
| 2017 | 23.5 | 0.09 | 10.68 | 3.05 | - |
| 2018 | 20.8 | 0.61 | 10.35 | 3.10 | - |
| 2019 | 19.9 | 2.23 | 6.88 | 2.83 | - |
| 2020 | 17.2 | 0.00 | 4.87 | 2.57 | - |
| 2021 | 24.2 | -0.75 | 4.24 | 2.05 | - |
| 2022 | 12.8 | 0.15 | 3.88 | 1.62 | - |
| 2023 | -319.1 | 3.11 | 2.73 | 1.02 | - |
| 2024 | -3.4 | 0.00 | 7.58 | 1.05 | - |
| 2025 | -12.8 | 0.21 | 72.13 | 1.83 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.83 | $908.3M | $35.2M | 3.9% |
| 2017 | $2.97 | $972.4M | $126.3M | 13% |
| 2018 | $3.97 | $1.13B | $169.1M | 14.9% |
| 2019 | $4.35 | $1.29B | $183.7M | 14.2% |
| 2020 | $4.37 | $1.22B | $181.4M | 14.9% |
| 2021 | $2.95 | $1.39B | $118.1M | 8.5% |
| 2022 | $5.50 | $1.67B | $211.6M | 12.7% |
| 2023 | $-0.15 | $1.69B | $-5.4M | -0.3% |
| 2024 | $-11.85 | $1.41B | $-430.3M | -30.6% |
| 2025 | $-4.61 | $1.17B | $-167.1M | -14.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $4.92 | $4.65 – $5.05 | $1.19B | $1.14B – $1.21B | 2 |
| 2027 | $5.98 | $5.66 – $6.14 | $1.19B | $1.14B – $1.22B | 2 |
| 2028 | $6.58 | $6.34 – $6.83 | $1.2B | $1.2B – $1.2B | 2 |
